Clinical trial

A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer

NCT03100955

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention cisplatin, etoposide Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention cisplatin, etoposide, apatinib Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2017-03-01

PhasePHASE3

Conditions

Progression Free Survivalunresolved

Interventions

cisplatin, etoposideDRUG

cisplatin, etoposide, apatinibDRUG

Sponsors & collaborators

Qingdao Universitylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03100955 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.